Skip to main content

Clinical Trials Using Anti-LAG-3 Monoclonal Antibody

Review the clinical trials studying anti-lag-3 monoclonal antibody on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 45

Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Status: Active
Location: 461 locations
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy after Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Status: Active
Location: 81 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 36 locations
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Status: Active
Location: 34 locations
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Status: Active
Location: 30 locations
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Status: Active
Location: 27 locations
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Status: Active
Location: 19 locations
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Status: Active
Location: 17 locations
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Status: Active
Location: 17 locations
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Status: Active
Location: 14 locations
Sacituzumab Govitecan plus Nivolumab, with or without Relatlimab, as Second-Line Treatment in Patients with Unresectable or Metastatic Triple Negative Breast Cancer, SIMONE Trial
Status: Active
Location: 12 locations
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Status: Active
Location: 11 locations
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Status: Active
Location: 10 locations
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Status: Active
Location: 12 locations
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People with Melanoma
Status: Active
Location: 8 locations
Cemiplimab and Fianlimab before Surgery for the Treatment of Patients with Locally Advanced Kidney Cancer Undergoing Nephrectomy
Status: Active
Location: 7 locations
Nivolumab, Relatlimab and Ipilimumab versus Nivolumab and Ipilimumab for the Treatment of Untreated Stage IV Renal Cell Cancer
Status: Active
Location: 6 locations
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Status: Active
Location: 5 locations
Sarilumab in Combination with Ipilimumab, Nivolumab, and Relatlimab for the Treatment of Unresectable Stage IIIB/C/D or Stage IV Melanoma
Status: Active
Location: 4 locations
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Status: Active
Location: 4 locations
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 4 locations
Immunotherapy in Combination with Radiation Therapy, with or without Platinum Doublet Chemotherapy, for the Treatment of Patients with Stage II or III Locally Advanced and Unresectable Non-Small Cell Lung Cancer, TRIPL Trial
Status: Active
Location: 2 locations
Neoadjuvant Opdualag versus Nivolumab for the Treatment of Resectable High-Risk Basal Cell Carcinoma
Status: Active
Location: 2 locations
A Microdevice for Candidate Drug Screening in Patients with Skin Squamous Cell Carcinoma
Status: Active
Location: 2 locations
ctDNA Guided Therapy with Ipilimumab, Nivolumab, and Relatlimab for the Treatment of Patients with Advanced, Metastatic or Unresectable Melanoma
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York